Learn More

Targeted Radioisotope Therapy Webinar Series

The new technologies of radionuclide therapy are allowing for personalized treatment of various forms of cancer. Learn more about the clinical utility of these procedures and earn free CE credit.

Healthcare Provider

Welcome to our Healthcare Provider portal. Everything you need to understand the advantages and applications of nuclear medicine and molecular imaging in your practice. Find out more about ordering the right test for the right patient at the right time.

What are Nuclear Medicine and Molecular Imaging?

Molecular imaging is a type of medical imaging that provides detailed pictures of what is happening inside the body at the molecular and cellular level. Where other diagnostic imaging procedures—such as x-rays, computed tomography (CT) and ultrasound—offer pictures of physical structure, molecular imaging allows physicians to see how the body is functioning and to measure its chemical and biological processes.

Molecular imaging includes the field of nuclear medicine, which uses very small amounts of radioactive materials (radiopharmaceuticals) to diagnose and treat disease. In nuclear medicine imaging, the radiopharmaceuticals are detected by special types of cameras that work with computers to provide very precise pictures of the area of the body being imaged. Nuclear medicine can also be used to treat certain types of cancer and  other diseases.

Molecular imaging offers unique insights into the human body that enable physicians to personalize patient care. In terms of diagnosis, molecular imaging is able to:

  • provide information that is unattainable with other imaging technologies or that would require more invasive procedures such as biopsy or surgery
  • identify disease in its earliest stages and determine the exact location of a tumor, often before symptoms occur or abnormalities can be detected with other diagnostic tests

Learn More


Disease-Specific Information


Cancer Scan


Heart Scan


Brain Scan


SNMMI has created guidelines to identify those elements of the procedure that are most important in obtaining a high-quality examination, Appropriate Use Criteria (AUC), and is working towards optimizing dose.

Appropriate Use Criteria
Dose Optimization

Related Resources

NCCN's Guidelines Tabular Summary
NCCN Practice Guidelines Narrative Summary

Ordering Information

The SNMMI PET Center of Excellence has created a go-to resource with in-depth ordering information and printable materials related to PET and PET/CT, including:

  • Sample Request Forms
  • Sample Letters of Medical Necessity
  • Sample Reports from Nuclear Medicine Physician
  • CMS Decision Memos

Learn More

Request a Speaker

SNMMI is dedicated to providing the community with access to the most knowledgeable and experienced speakers in the field of nuclear medicine and molecular imaging. As part of the new Outreach Program, SNMMI is working to enhance relationships with relevant societies and patient organizations. We have created a pool of speakers who can speak at your next meeting. Please complete the form below to request a speaker.

Outreach Speaker Request Form
Outreach Program



  • October 1, 2014FDG-PET/CT Shows Promise for Breast Cancer Patients Younger Than 40

    Researchers at Memorial Sloan Kettering found that PET/CT imaging of patients younger than 40 who were initially diagnosed with stage I–III breast cancer resulted in change of diagnosis. As reported in the October issue of The Journal of Nuclear Medicine, while guidelines recommend FDG-PET/CT imaging only for women with stage III breast cancer, it can also help physicians more accurately diagnose young breast cancer patients initially diagnosed with earlier stages of the disease.
    (Press Release)

  • October 1, 2014Flurpiridaz PET MPI data reveal lower dose than conventional SPECT

    Myocardial perfusion imaging (MPI) with PET and F-18 flurpiridaz may reduce radiation dose while still providing comparable image quality to SPECT, the current standard, according to a study presented at the recent American Society of Nuclear Cardiology (ASNC) Annual Scientific Session held in Boston from Sept 18-21.
    (MI: Making a Difference)

  • September 30, 2014New imaging technique provides hope for deadly childhood cancer

    Cancer Research UK’s Centre for Drug Development (CDD), in collaboration with the Rising Tide Foundation (link is external), a Swiss-based non-profit organisation which funds innovative cancer trials, today (TUESDAY) announce a new trial at The Royal Marsden (link is external)and University College London (link is external)that could revolutionise how children with one of the deadliest forms of cancer are diagnosed. The news falls in Children’s Cancer Awareness Month, which runs throughout September.
    (MI: Making a Difference)

  • September 26, 2014Prognostic PET/CT is superior to CT for follicular lymphoma

    A retrospective study gauging the benefit of PET/CT after first-line therapy for follicular lymphoma in multi-center trials puts PET/CT on a pedestal above CT alone as a tool for gauging patients’ response to therapy and prospective survival, according to a study published Sept. 18 in The Lancet Haematology .
    (MI: Making a Difference)

Featured Resources

  • Guidance

    Tools, supported by evidence, to harmonize the practice of nuclear medicine using a progressive and safe approach.

  • Legislative Issues

    SNMMI monitors multiple federal legislative issues and provides resources including issue summaries, letters to Congress, and analysis.

  • Annual Reports

  • Journals

    Learn more about journals published by or sponsored by the Society of Nuclear Medicine and Molecular Imaging.